EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype

Timothy F Burns, Sanja Dacic, Anish Chakka, Ethan Miller, Maria A Velez, Ashwin Somasundaram, Saveri Bhattacharya, Autumn Gaither-Davis, Princey Devadassan, Jingxiao Jin, Vinod Kumar, Arjun Pennathur und 8 weitere

Journal of Clinical Investigation · 16.02.2026 · 136 (4)

DOI: 10.1172/jci194708 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 18.12.2025. Verfasst von Timothy F Burns und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, and. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-met, Brain Neoplasms, Lung Neoplasms, Adenocarcinoma of Lung. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute of the National Institutes of Health, American Cancer Society Research Scholar Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non–small cell lung cancer exhibits the highest rates of brain metastases (BMs) among all solid tumors, presenting a major clinical challenge. The development of novel therapeutic strategies targeting BMs is clearly needed. We identified a significant enrichment of MET amplification in lung adenocarcinoma (LUAD) BMs compared with primary LUAD and extracranial metastases in oncogene driver–negative patients. Of note, MET -amplified BMs were responsive to MET inhibitors in vivo, including models with acquired MET amplification at the time of metastasis. MET alterations (amplifications and/or mutations) were also more frequently detected in circulating tumor DNA from patients with LUAD BMs than in those without BMs. MET- altered BMs also demonstrated unique genomic features compared with non– MET- altered BMs. Transcriptomic analyses revealed that in contrast to MET WT BMs, MET -amplified BMs exhibited a more inflamed tumor microenvironment and displayed evidence of metabolic adaptation, particularly a reliance on glycolysis in contrast to OXPHOS in MET WT BMs. Furthermore, MET -amplified BMs demonstrated evidence of epithelial-mesenchymal transition signaling, including increased expression of TWIST1. Patients with MET -amplified BMs had significantly shorter overall survival. These findings highlight MET amplification as a critical driver of LUAD BMs, emphasizing its potential as a therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-metBrain NeoplasmsLung NeoplasmsAdenocarcinoma of LungHumansFemaleMaleAnimalsGene AmplificationMiceEpithelial-Mesenchymal TransitionTumor MicroenvironmentMutationCell Line, TumorNuclear ProteinsTwist-Related Protein 1

Stichwörter der Autor:innen

BiomarkersGeneticsLung cancerOncogenesOncology

Substanzen

Proto-Oncogene Proteins c-metMET protein, humanTWIST1 protein, humanNuclear ProteinsTwist-Related Protein 1

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Department of Medicine, and.
  • Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
  • Department of Pathology.
  • Department of Bioinformatics, and.
  • Department of Cardiothoracic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Förderung

  • NCI NIH HHS
  • National Cancer Institute of the National Institutes of Health
  • American Cancer Society Research Scholar Award
  • The University of Pittsburgh Institute for Precision Medicine
  • Libby’s Lungs
  • We Wish Foundation
  • U.S. Department of Defense

Zitieren

APA

Burns, T. F., Dacic, S., Chakka, A., Miller, E., Velez, M. A., Somasundaram, A., Bhattacharya, S., Gaither-Davis, A., Devadassan, P., Jin, J., Kumar, V., Pennathur, A., Xiu, J., Oberley, M., Glantz, M. J., Aulakh, S., Chandran, U. R., Bao, R., Tatsuoka, C., & Stabile, L. P. (2026). MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype. Journal of Clinical Investigation, 136(4). https://doi.org/10.1172/jci194708

Vancouver

Burns TF, Dacic S, Chakka A, Miller E, Velez MA, Somasundaram A, et al. MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype. Journal of Clinical Investigation. 2026;136(4). doi:10.1172/jci194708

BibTeX
@article{Burns2026,
  author = {Burns, Timothy F and Dacic, Sanja and Chakka, Anish and Miller, Ethan and Velez, Maria A and Somasundaram, Ashwin and Bhattacharya, Saveri and Gaither-Davis, Autumn and Devadassan, Princey and Jin, Jingxiao and Kumar, Vinod and Pennathur, Arjun and Xiu, Joanne and Oberley, Matthew and Glantz, Michael J and Aulakh, Sonikpreet and Chandran, Uma R and Bao, Riyue and Tatsuoka, Curtis and Stabile, Laura P},
  title = {MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {4},
  doi = {10.1172/jci194708}
}
Kostenlos starten →